Available Trials

Prostate Cancer

  • PROSTATE USO 16159

    A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of An Androgen Synthesis inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen

    Available at 6 locations